Synthesis, characterization and in vitro studies of pegylated melphalan conjugates

Drug Development and Industrial Pharmacy

Volumn 39, Issue 7, 2013, Pages 1053-1062

  Ajazuddin, ^a   Alexander, Amit ^a   Amarji, Basant ^b   Kanaujia, Parijat ^c  

^a RUNGTA COLLEGE OF PHARMACEUTICAL SCIENCES AND RESEARCH   (India)

^b PANJAB UNIVERSITY   (India)

^c INSTITUTE OF CHEMICAL AND ENGINEERING SCIENCES   (Singapore)

Author keywords

Anti cancer; Aqueous solubility; Hemolytic activity; MCF 7 cell line; Methoxy polyethylene glycol

Indexed keywords

MACROGOL 2000; MELPHALAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONCENTRATION (PARAMETERS); DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG SOLUBILITY; DRUG SYNTHESIS; HEMOLYSIS; HUMAN; HUMAN TISSUE; HYDROLYSIS; IN VITRO STUDY; LD 50; MOLECULAR WEIGHT; NUCLEOPHILICITY; STEREOSPECIFICITY;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CHROMATOGRAPHY, THIN LAYER; DRUG STABILITY; HUMANS; HYDROLYSIS; MELPHALAN; POLYETHYLENE GLYCOLS; SOLUBILITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84869503987     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.702346     Document Type: Article

References (42)

1. Niranjan NP, John HM, John HP. (1996). Synthesis of Co-Drugs of Alkylating Agents and Steroidal Anti-Inflammatories. Drug Dev Ind Pharm, 22:181-184.
2. Sarosy G, Leyland-Jones B, Soochan P, Cheson BD. (1988). The systemic administration of intravenous melphalan. J Clin Oncol, 6:1768-1782.
3. Samuels BL, Bitran JD. (1995). High-dose intravenous melphalan: a review. J Clin Oncol, 13:1786-1799.
4. Jonkman-De Vries JD, Flora KP, Bult A, Beijnen JH. (1996). Pharmaceutical Development of (Investigational) Anticancer Agents for Parenteral Use-A Review. Drug Dev Ind Pharm, 22:475-494.
5. David Attivi, Imane Ajana, Alain Astier, Béatrice Demoré, Stéphane Gibaud. (2010). Development of microemulsion of mitotane for improvement of oral bioavailability. Drug Dev Ind Pharm, 36:421-427.
6. Geerligs IEJ, Beijnen JH, Bekers O, Underberg WJM. (1993). Quality Control of Protein and Peptide Drugs: Monoclonal Antibodies and some Biological Response Modifiers Derived by Recombinant DNA Technology. Drug Dev Ind Pharm, 19:33-84.
7. Tracy Chen. (1992). Formulation concerns of protein drugs. Drug Dev Ind Pharm, 18:1311-1354.
8. Lockman PR, Mumper RJ, Khan MA, Allen DD. (2002). Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm, 28:1-13.
9. Choi KE, Ratain MJ, Williams SF, Golick JA, Beschorner JC, Fullem LJ et al. (1989). Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. Cancer Res, 49:1318-1321.
10. Cuilian Peng, Cong Liu, Xing Tang. (2010). Determination of physicochemical properties and degradation kinetics of triamcinolone acetonide palmitate in vitro. Drug Dev Ind Pharm, 36:1469-1476.
11. Kalle Sigfridsson, Anders Lundqvist, Marie Strimfors. (2011). Co-administration of a nanosuspension of a poorly soluble basic compound and a solution of a proton pump inhibitor - the importance of gastrointestinal pH and solubility for the in vivo exposure. Drug Dev Ind Pharm, 37:1036-1042.
12. Katharina Leithner, Vjera Grabovac, Karin Albrecht, Juliane Hombach, Günter Klima. (2011). Andreas Bernkop-Schnürch. Permeation studies on freshly excised rat gastric mucosa: influence of pH. Drug Dev Ind Pharm, 37:518-525.
13. Yue-Hua Liu, Xi Zhu, Dan Zhou, Yun Jin, Chun-Yan Zhao, Zhi- Rong Zhang, Yuan Huang. (2011). pH-Sensitive and mucoadhesive microspheres for duodenum-specific drug delivery system. Drug Dev Ind Pharm, 37:868-874.
14. Evans TL, Chang SY, Alberts DS, Sipes IG, Brendel K. (1982). In vitro degradation of L-phenylalanine mustard (L-PAM). Cancer Chemother Pharmacol, 8:175-178.
15. Tegafur José L. Arias, Margarita López-Viota, Visitación Gallardo, María Adolfina Ruiz. (2010). Chitosan nanoparticles as a new delivery system for the chemotherapy agent. Drug Dev Ind Pharm, 36:744-750.
16. Shimon Ben-Shabat, Nir Baruch, Amnon C. Sintov. (2007). Conjugates of Unsaturated Fatty Acids with Propylene Glycol as Potentially Less-Irritant Skin Penetration Enhancers. Drug Dev Ind Pharm, 33:1169-1175.
17. Yoncheva K, Doytchinova I, Irache JM. (2010). Different approaches for determination of the attachment degree of polyethylene glycols to poly(anhydride) nanoparticles. Drug Dev Ind Pharm, 36:676-680.
18. Ajazuddin, Saraf S. (2010). Applications of novel drug delivery system for herbal formulations. Fitoterapia, 81:680-689.
19. Enam Khalil, Najjar S, Sallam A. (2000). Aqueous Solubility of Diclofenac Diethylamine in the Presence of Pharmaceutical Additives: A Comparative Study with Diclofenac Sodium. Drug Dev Ind Pharm 26:375-381.
20. Andrei Dashevsky, Abid Riaz Ahmed, Mota J, Muhammad Irfan, Karl Kolter, Roland A Bodmeier. (2010). Effect of watersoluble polymers on the physical stability of aqueous polymeric dispersions and their implications on the drug release from coated pellets. Drug Dev Ind Pharm, 36:152-160.
21. Hooftman G, Herman S, Schacht E. (1996). Poly (Ethylene Glycol) s with Reactive Endgroups. II Practical Consideration for the Preparation of Protein-PEG Conjugates. J Bioact Compat Polymers, 11:135-159.
22. Lu ZR, Kopecková P, Wu Z, Kopecek J. (1998). Functionalized semitelechelic poly[N-(2-hydroxypropyl)methacrylamide] for protein modification. Bioconjug Chem, 9:793-804.
23. Russ Middaugh. (2008). A Review of: Vaccine Adjuvants and Delivery Systems. Drug Dev Ind Pharm, 34:347-347.
24. Richter AW, Akerblom E. (1983). Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol, 70:124-131.
25. Vandegriff KD, McCarthy M, Rohlfs RJ, Winslow RM. (1997). Colloid osmotic properties of modified hemoglobins: chemically cross-linked versus polyethylene glycol surface-conjugated. Biophys Chem, 69:23-30.
26. Abuchowski A, van Es T, Palczuk NC, Davis FF. (1977). Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem, 252:3578-3581.
27. Working PK, Newman MS, Johnson J, Harris JM, Zalipsky S. (1997). Poly (ethylene glycol) Chemistry and Biological applications. ACS Books: Washington DC; 45-57.
28. Kurtzberg J, Holland JF, Bast RC, Morton DL, Frei E, Kufe JW, Weichselbaum RR. (1997). Cancer medicine: 4th edition, Baltimore, MD, Lippincott Williams and Wilkins 1027-1036.
29. Wang YS, Youngster S, Bausch J, Zhang R, McNemar C, Wyss DF. (2000). Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry, 39:10634-10640.
30. Yousefi G, Foroutan SM, Zarghi A, Shafaati A. (2010). Synthesis and characterization of methotrexate polyethylene glycol esters as a drug delivery system. Chem Pharm Bull, 58:147-153.
31. Jasmin K, Martina M, Juergen S, Peter LT, Hans PS, Günter A. (2010). GEMMA and MALDI-TOF MS of reactive PEGs for pharmaceutical applications. J Pharm Biomed Anal, 52:432-437.
32. Vandermeulen G, Rouxhet L, Arien A, Brewster ME, Préat V. (2006). Encapsulation of amphotericin B in poly(ethylene glycol)-blockpoly (epsilon-caprolactone-co-trimethylenecarbonate) polymeric micelles. Int J Pharm, 309:234-240.
33. Williams RO III. (2006). A Review of: "Pharmaceutical Dissolution Testing". Drug Dev Ind Pharm, 32:401-401.
34. Williams, RO III. (2006). A Review of: "HPCL Methods for Recently Approved Pharmaceuticals". Drug Dev Ind Pharm, 32:907-907.
35. Wang X, Tian Y, Hansen L, Zang L. (2010). Preparation and characterization of PEGylatedterlipressin. J Appl Poly Sci, 116: 3220-3224.
36. Conover CD, Pendri A, Lee C, Gilbert CW, Shum KL, Greenwald RB. (1997). Camptothecin delivery systems: the antitumor activity of a camptothecin-20-0- polyethylene glycol ester transport form. Anticancer Res, 17:3361-3368.
37. Conover CD, Greenwald RB, Pendri A, Gilbert CW, Shum KL. (1998). Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother Pharmacol, 42:407-414.
38. Greenwald RB, Pendri A, Bolikal D, Gilbert CW. (1994). Highly water soluble taxol derivatives: 2-polyethyleneglycol estersas potential prodrugs. Bioorg Med ChemLett, 4:2465-2470.
39. Greenwald RB, Choe YH, McGuire J, Conover CD. (2003). Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev, 55:217-250.
40. Monfardini C, Schiavon O, Caliceti P, Morpurgo M, Harris JM, Veronese FM. (1995). A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem, 6:62-69.
41. Lavasanifar A, Samuel J, Kwon GS. (2002). The effect of fatty acid substitution on the in vitro release of amphotericin B from micelles composed of poly(ethylene oxide)-block-poly(N-hexyl stearate-Laspartamide). J Control Release, 79:165-172.
42. Neta P, Mika R, Marina S, Ferda Y, Hong X, Katherine NS, Gil A, Doron S. (2004). Bioactivation of carbamate-based 20(S)-camptothecinprodrugs. Bioorg Med Chem, 12:185-186.